Clinical Study on the Safety, Efficacy, and Exploration of Immune Mechanisms of a Combined Multimodal Tumor Therapy System for Hepatic Malignancies
Age 18-80 years, regardless of gender;
Histopathologically confirmed or clinically diagnosed hepatic malignancies, including primary liver cancer and metastatic liver cancer;
Presence of an image-evaluable target lesion for ablation, with the maximum diameter of the target lesion being 3-5 cm;
Patient is intolerant to or refuses surgical resection;
Liver function classified as Child-Pugh C, unimprovable with hepatoprotective therapy;
Massive or diffuse hepatocellular carcinoma;
Presence of vascular tumor thrombus or invasion of adjacent organs;
History of esophageal (gastric fundus) variceal rupture and bleeding within 1 month prior to treatment;